Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 44

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 3
Chunk 44
---
 minimum bid price requirement exists if the deficiency
continues for a period of 30 consecutive business days. The notification provided that we had 180 calendar days, or until November 11,
2024, to regain compliance with Nasdaq Listing Rule 5550(a)(2). Since we did not regain compliance by November 11, 2024, we requested
and received from Nasdaq an additional 180 calendar days, or until May 12, 2025, to comply with the minimum bid price. On January 30,
2025, we effected a change in the ratio of our ADSs to ordinary shares from one ADS representing 15 ordinary shares to a new ratio of
one ADS representing 600 ordinary shares. As a result, on February 13, 2025, we received a notice from Nasdaq indicating that we regained
compliance with the minimum bid price requirement under Nasdaq Rules 5550(a)(2).

No assurance can be given that we will be able to maintain a minimum
bid price of $1.00 per ADS. If we do not meet the minimum bid price requirement or other continued listing requirements, our ADSs could
be delisted. A delisting of our ADSs from Nasdaq could materially reduce the liquidity of our ADSs and result in a corresponding material
reduction in the price of our ADSs. In addition, delisting could harm our ability to raise capital through alternative financing sources
on terms acceptable to us, or at all, and may result in the potential loss of confidence by investors, employees and fewer business development
opportunities and strategic alternatives. There can be no assurance that our ADSs, if delisted from the Nasdaq Capital Market in the future,
would be listed on a national securities exchange, a national quotation service, the Over-The-Counter Markets or the pink sheets. Delisting
from the Nasdaq Capital Market, or even the issuance of a notice of potential delisting, would also result in negative publicity, make
it more difficult for us to raise additional capital, adversely affect the market liquidity of our ADSs, reduce security analysts’
coverage of us and diminish investor, supplier and employee confidence. Additionally, the threat of delisting or the delisting of our
ADSs from the Nasdaq Capital Market could reduce the number of investors willing to hold or acquire our ADSs, thereby further restricting
our ability to obtain equity financing, and it could reduce our ability to retain, attract and motivate our directors, officers and employees